SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
GoHealth, Inc. (GOCO) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1,963.89%, forward earnings yield 555.56%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+367.3%).
- Forward P/E 0.2 — analysts expect a return to profitability with estimated EPS of $6.00 for FY2028.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -1,963.89% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 555.56% as earnings recover.
- Analyst consensus target $5.00 (+367.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GOCO
Valuation Multiples
P/E (TTM)-0.1
Forward P/E0.2
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.14
P/S Ratio0.08
EV/EBITDA-2.0
Per Share Data
EPS (TTM)$-19.87
Forward EPS (Est.)$6.00
Book Value / Share$-0.41
Revenue / Share$27.96
FCF / Share$-10.03
Yields & Fair Value
Earnings Yield-1,963.89%
Forward Earnings Yield555.56%
Dividend Yield0.00%
SharesGrow IV$-36.60 (-3520.9%)
Analyst Target$5.00 (+367.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
217.0 |
0.00 |
-32.69 |
26.98 |
- |
| 2019 |
-148.6 |
0.60 |
7.09 |
11.31 |
- |
| 2020 |
-26.0 |
-0.38 |
3.02 |
1.31 |
0.03% |
| 2021 |
-2.1 |
0.00 |
1.14 |
0.38 |
- |
| 2022 |
-0.6 |
0.02 |
0.28 |
0.14 |
- |
| 2023 |
-2.0 |
0.03 |
0.44 |
0.17 |
2.88% |
| 2024 |
-45.6 |
0.50 |
0.45 |
0.17 |
- |
| 2025 |
-0.1 |
0.00 |
0.29 |
0.08 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$1.34 |
$226.21M |
$28.12M |
12.4% |
| 2019 |
$-7.32 |
$539.5M |
$-41.07M |
-7.6% |
| 2020 |
$-3.30 |
$877.35M |
$-44.27M |
-5% |
| 2021 |
$-26.85 |
$1.06B |
$-189.36M |
-17.8% |
| 2022 |
$-17.72 |
$631.68M |
$-148.71M |
-23.5% |
| 2023 |
$-7.19 |
$734.67M |
$-63.26M |
-8.6% |
| 2024 |
$-0.29 |
$798.89M |
$-2.93M |
-0.4% |
| 2025 |
$-20.17 |
$361.85M |
$-257.13M |
-71.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-6.63 |
$-8.87 – $-5.38 |
$316.46M |
$223.4M – $394.23M |
3 |
| 2027 |
$-2.84 |
$-3.75 – $-1.91 |
$585.37M |
$579.25M – $589.07M |
3 |
| 2028 |
$6.00 |
$5.23 – $6.74 |
$1.11B |
$996.44M – $1.21B |
1 |
| 2029 |
$8.00 |
$6.97 – $8.99 |
$1.18B |
$1.07B – $1.3B |
1 |
